Tobin Arthur Joins Panel at Texas Life Science Venture Forum

San Francisco, CA (PRWEB) February 18, 2014  —  angelMD, the funding platform that connects physicians and leading medical startups, today announced that CEO Tobin Arthur will be participating on a crowd-funding panel as part  of the Texas Life Science Venture Forum.

“Texas is one of the strongest healthcare innovation and care delivery markets in the world and angelMD is deeply active throughout the state,” said Mr. Arthur.  “Part of the conference is focused on answering the question of whether crowd-funding is an effective option for medical startups needing to raise capital and we look forward to offering our perspective.”

The Texas Life Science Forum is taking place February 20, 2014 from 8:00 to 6:30PM at BioScience Research Collaborative in Houston, Texas. The event showcases early-stage technology companies and provides companies with exposure to investors, partners, mentors, customers, and other individuals who support the entrepreneurial ecosystem.

The event is hosted by BioHouston, Rice Alliance for Technology and Entrepreneurship, and the Texas Healthcare and Bioscience Institute.

About angelMD

Based in San Francisco, California and Seattle, Washington, angelMD is a healthcare investment marketplace leveraging a powerful crowd-funding platform that connects physician investors with innovative medical startups seeking capital investments, advisors, and users.

Leading physicians from all over the US have joined the angelMD Clinical Advisory Board and Leaders Club to help source and evaluate opportunities in biotechnology, medical device and healthcare technology. For more information visit


Darci Moreau  /  / 650.389.9595 x 700

Continue reading

angelMD Loves Its medical team

San Francisco, CA (PRWEB) February 14, 2014angelMD, a healthcare investment marketplace, today announces the addition of 3 leading clinicians to its senior management team.  The company’s medical team, including its extensive Clinical Advisory Board, is led by Klaus Mergener, MD, PhD, MBA a thought-leading gastroenterologist. Dr. Mergener is joined by Charles Weaver, MD an oncologist and entrepreneur who leads the company’s efforts to build a nationwide network of physician investors. Dr. Michael Dillingham joins the team as the Medical Director overseeing operations in the Bay Area to include working with leading medical startups and physician investors in one of the most innovative markets in the world.

“Our firm is physician centric to the core. We are honored to have an incredibly high caliber group of physicians on the senior management team bringing a very diverse set of backgrounds to the organization.” said Tobin Arthur, angelMD Chief Executive Officer. Adds Klaus Mergener, MD, PhD, MBA angelMD Chief Medical Officer, “Many small and large companies alike get the business and scientific parts of their business right but neglect clinical considerations. angelMD’s medical team and its investor network ensure that companies are building ventures that are going to be effective for patients and also successful in the marketplace.”

Physician Biographies

Klaus Mergener, MD, PhD, MBA (Chief Medical Officer): attended medical school in Frankfurt and Heidelberg, Germany, and at Duke University and Harvard University in the U.S. He received his medical degree from Ruprecht-Karls-University in Heidelberg before completing his Ph.D. work with 2008 Nobel Prize Laureate Harald zur Hausen at the German Cancer Research Center in Heidelberg where he graduated “Summa Cum Laude”. Dr. Mergener returned to Duke University for his residency in internal medicine and fellowship training in gastroenterology, and he completed an additional year of interventional endoscopy at the same institution. He received his MBA from the University of Massachusetts at Amherst.

Dr. Mergener is a diplomat in several national medical organizations and is board-certified in Gastroenterology, Medical Management, and Healthcare Quality Management. He currently serves as the Medical Director for Gastroenterology at MultiCare Health System in Tacoma, WA, and as Director of GI Hospitalist Services at Digestive Health Specialists, the largest single specialty gastroenterology practice in the Pacific Northwest. In 2013, Dr. Mergener was appointed Affiliate Professor of Medicine at the University of Washington in Seattle, WA.

Dr. Mergener is a current member of the Governing Board of the American Society for Gastrointestinal Endoscopy (ASGE) and Associate Editor of Gastrointestinal Endoscopy. He served as GI Governor for Washington State for the American College of Gastroenterology (ACG) and as CPT and RUC Advisor to the AMA CPT Editorial Panel and the Relative Value Update Committee (RUC). Dr. Mergener has received Fellowship designations from ASGE, ACG, the American College of Physicians (ACP), and the American College of Physician Executives (ACPE).

Dr. Mergener’s areas of clinical expertise include biliary and pancreatic diseases, interventional endoscopy and cancer prevention. He has authored more than 100 articles and book chapters and has presented over 150 invited lectures at regional, national, and international conferences. Becker’s ASC Review recently named him as one of the nation’s “Top Gastroenterologists”.

In addition to his clinical activities, Dr. Mergener serves on several advisory panels for endoscopic equipment and accessory manufacturers. He helps medical device developers and investors evaluate new technology opportunities in the medical space. He has assisted companies in all stages of the FDA submission process and with payor negotiations. He has made presentations to government agencies, business leadership and to a variety of industry groups across the US and abroad. Dr. Mergener is the co-founder of the GI Roundtable, a national network of over 300 GI practice leaders and administrators.

Charles H. Weaver, MD (SVP Clinical and Business Development) is a former cancer researcher, developer of the Physician Practice Management industry and pioneer of Internet-based cancer education. Dr. Weaver received his medical training at the University of Pennsylvania, National Institutes of Health and Fred Hutchinson Cancer Research Center. He served five years as the Chief Medical Officer of a PPM company, where he created the clinical trials network, developed cancer treatment strategies and pathways, oversaw managed care contracting and the educational programs used by over 750 oncologists in the U.S.

In 1998, Dr. Weaver founded, an award-winning, leading Internet cancer portal and social media platform used by over 100 oncology clinics and leading cancer centers including Dana Farber and Memorial Sloan Kettering Cancer Centers. He is significantly involved with Cancer Advocacy, Education and Women’s Health issues, recently appearing on The Today Show to discuss these issues.  He has written extensively on all aspects of cancer management, and is the Executive Editor and Publisher of Women Magazine, a quarterly magazine dedicated to covering cancer prevention, treatment and wellness issues for all women.

Dr. Weaver’s initial clinical research interests included stem cell transplantation in breast cancer and lymphomas where he authored ~ 75 articles in major medical journals including the Journal of Clinical Oncology, Blood, Cancer, Bone Marrow Transplantation and the New England Journal of Medicine.  He has given grand rounds and lectured internationally on stem cell treatments at The University of London, The University of Heidelberg, Duke, Stanford, Georgetown and over 100 other cancer centers.

His unique career path encompassing stem cell research, drug development, practice management, managed care contracting, marketing, and market research combined with 20 years experience in print and web based education and media development has led to significant strategic technology and market assessment consulting relationships within healthcare including Amgen, Immunex, Genomics Health, Novartis, Glaxo Wellcome, Spectrum Pharmaceuticals as well as earlier stage biopharmaceutical companies and health care delivery networks and systems.

Michael F. Dillingham, MD (Regional Medical Director – Bay Area): is the co-founder of Sports Orthopedic and Rehabilitation Medical Associates (SOAR).  He is Board Certified in both Orthopedic Surgery and in Physical Medicine and Rehabilitation.  His undergraduate, medical school, and residencies were all completed at Stanford University.  He also completed a fellowship in Spinal Cord Injury.

After a period as Associate Chief of Physical Medicine and Rehabilitation at Santa Clara Valley Medical Center he returned to Stanford initially as Assistant Chief of Orthopedics and Rehabilitation at Stanford Children’s Hospital and later as Director of the Adult Neuromuscular Clinic and the Sports Medicine Clinic in the Department of Orthopedics.

Since starting SOAR in 1981 Dr Dillingham has provided state of the art medicine to numerous Professional, Olympic and collegiate athletes and teams.  He and his unique mix of surgical, physiatric, rheumatologic and primary care colleagues at SOAR have developed a comprehensive model of musculoskeletal care.  From 1983 to 2007 Dr Dillingham was the team physician for the San Francisco Forty Niners.  He has been team physician for Santa Clara University since 1992.  In 1993 he was named Director of Orthopedics for Stanford Athletics and in 1996 he became Director of Sports Medicine for Stanford Health Services helping to oversee the musculoskeletal care of all Stanford sports teams a position and remained a team physician at Stanford until 2007.  Since 2003 he has been a consultant with the San Francisco Giants becoming a team physician in 2011.  He has been a Clinical Professor of Orthopedics at Stanford since 2003.

Dr Dillingham is past President of the National Football League Team Physician Society.  During his tenure the Society was formally incorporated and initiated a recognized relationship with the League that continues today fostering research and safety in professional football.

Dr Dillingham has long had an interest in real world accounting and analysis of health care costs not just the dollars spent in the narrow health care silo.  He was the Director of the Medical Board for Roadway Trucking analyzing and controlling the real cost of care.  He served as CMO of Claimetrics, a worker compensation insurance company and has consulted with Employer Direct Health.  He has also been involved in medical device development with companies including Coherent Laser, Oratec (radiofrequency surgical technology), Stryker, Biomet, EBI, Stabilynx (arthroscopic anchors), Lauramed (spine and ENT) and several fitness and fitness device companies.

About angelMD

Based in San Francisco, California and Seattle, Washington, angelMD is a healthcare investment marketplace leveraging a powerful crowd-funding platform that connects physician investors with innovative medical startups seeking capital investments, advisors, and users.  For more information, visit  Leading physicians from all over the US have joined the angelMD Clinical Advisory Board and Leaders Club to help source and evaluate opportunities in biotechnology, medical device and healthcare technology.


Darci Moreau  /  / 650.389.9595 x 700

Continue reading

Crowdfunding: Managing Risk

Crowdfunding represents an extraordinary opportunity for innovators to more efficiently raise money to bring their new ideas to market.  It can be an effective alternative to the traditional ways to finance tuning an idea into a business.  angelMD is part of this paradigm shift, targeting life science and healthcare start-ups in the earlier stages of their life cycle, a time when funding is either not available or extremely inefficient to aggregate. The opportunities for innovators and physician investors are almost limitless in today’s rapidly changing healthcare environment, and angelMD is fully engaged.

Crowdfunding success stories abound, but for every upside, there is a downside.  A recent article in Inside Counsel, “Technology: Caution before you crowdfund! (Part One) — While crowdfunding may not require any up-front costs, it is certainly not risk free”, points to some of the risks and misadventures in this relatively new part of the country’s financial system (

The angelMD team set out to create an environment that minimizes the opportunity for misunderstandings among the participants.  Rather than exclusively “relying on the wisdom of the crowd” to select good investments, angelMD designed a platform to streamline the best practices already developed by institutional investors and put them to work directly for individual physicians.  The angelMD platform helps educate startups and investors (neither of which may have professional expertise at raising or investing capital) by guiding them to well-documented and structured transactions which are fully understood by the parties.  angelMD disintermediates and democratizes the market for early-stage capital without turning the “crowd” into a “mob.”

There are a few keys to angelMD’s approach:  First, angelMD provides an initial filter to startups registering on the platform. While this not an endorsement of these companies, it provides a basic quality control step ensuring companies are medically focused and are organized as legal entities that could accept investment capital.  Second, companies that are presented to the network for funding undergo a rigorous curation and screening process.  This process does not replace the due diligence of the investors in the network, but it helps assure that the key material needed for an investor to make an informed decision is readily available in a standardized format for efficient review and comparison.  Next, angelMD takes an active role in managing investments ensuring its investor network receives regular updates and getting directly involved when its network of physicians can offer assistance to a portfolio company.

Successful investing is hard work and requires time.  angelMD exists to shift the risk needle in the favor of its investors and investments, increasing the odds of successful returns.  In the process we provide a more efficient marketplace for both startups and investors.

Continue reading

Innovation Can be Subtle

As a long-time observer of our country’s healthcare system, and a reluctant participant from time to time, I have been fascinated by the contradiction of amazing innovation in medical care (think gene therapy or regenerative medicine, for example) and sluggish change in the systems that surround that care (think about the slow growth in truly interactive EHRs or the lack of any real positive connection between the health plan and the enrollee).  However, change may finally be coming as noted in “Let me help you help me help you: How payers are using technology to boost engagement” in the January 24 edition of MedCity News.

Health plans are rapidly acquiring the electronic tools that permit a more direct link between the insured and the insurer.  Part of it may be slick marketing, trying to find new ways to attract the business of a younger generation raised on electronic connections of many kinds.  No matter the healthcare issue, we know that “there is an app for that.”  However, another part may be responding to the new market rules created by the Affordable Care Act.  Health plans no longer can use the underwriting tools of old, and must find new ways to remain profitable.  Suddenly keeping the population that is in the company’s insurance pool healthy is critical to the bottom line.  It is no longer easy to cull the weak or the sick out of the health plan.

Integrating technology, by corporate acquisition, allows the Anthems and the Aetnas of the world to encourage, support or perhaps berate their beneficiaries into adopting healthier behaviors.   Innovators are constantly finding new ways to enhance our electronic connections on many fronts and these new tools can find their way into healthcare.  This trend will be likely to grow as the whole of the Affordable Care Act is implemented.  Innovators may want to look at the examples in the article and move quickly if they see a good match for their skills and the needs of health plans.  angelMD might be just the platform to launch that next good idea.  Physicians as investors, take note.  There may be some solid investment opportunities here, with the big cash prize coming from the health plan acquisition.

It will be interesting and instructive to see if this new wave of tech savvy insurance companies can make a real difference in population and individual health.  Of course it will also be interesting to see if these health plan efforts enhance or impede communications between the health plan enrollees and the physicians who care for them.  There’s probably an app for that, too.

Continue reading

Meeting Startups at J.P. Morgan Annual Healthcare Conference

angelMD is at the J.P. Morgan Annual Healthcare Conference in San Francisco. Today, we met leaders from several startups who recorded quick video introductions.

This is Ivana from

And this is Adam, also from

This is Laurence from Prevently

And this is Kristin, also from Prevently

This is Suresh from GestInTime

Right now we’re about to participate in the conference tweet up. You can follow #jpm14 to watch the conference-related tweets.

Continue reading